*See RBI status quo on April 1, CPI inching to 8.5%: Nomura.
*Under-promising old Murthy trick; Infosys can surprise: Envision.
*USFDA ban may not affect Sun Pharma financially: JM Fin.
*Copper selloff overdone; bearish on gold: StanChart.
*China is growing at 4% and that’s okay: Marc Faber.
*Facebook COO Sandberg eyed for top job at Disney.
*Candy Crush maker King files for IPO to raise $532.8mn.
*IPL 7 insurance cover may shrink as it moves to UAE, Bangladesh.
*Roy’s Tihar stay continues as SC refuses bail.
*CBI carries out searches at NSEL office, 15 locations.
*Sebi panel suggests revision of fees for market entities.
*Compat to hear Coal India plea against CCI penalty next month.
*Compat to hear plea against Jet-Etihad deal later this month.
*Dr Reddy’s recalls some lots of heartburn drug in US.
*Sun Pharma dips on FDA import alert for Karkhadi unit.
*L&T gains on winning Rs 3,655 crore order from Qatar.
*See 7-10% volume growth; upbeat local biz helping: Allcargo.
*Manappuram up 4% on Milestone Home Fin acquisition.
*Tata Motors rises as JLR February sales jump 14%.
*Manpower required for aviation might grow to 1.17 lakh by 2017.
*Spicejet allots warrants worth Rs 133.2 crore to promoters.
*Award of Rs 49,200 cr Odisha, Tamil Nadu UMPPs pushed to June.
*Cash transactions will be scrutinised by law enforcement agencies: FMC.
*Sesa Sterlite to move court on lay offs: Official.
*Jubilant Life up 3.4%, hikes price of vitamin B3 ingredient.
*New US gas legislation could boost exports to India.
*Gas price hike, lower subsidies to boost OIL India’s prospects.
*Maruti replies to Sebi, clarifies on Guj fiasco: Sources.
*Hero launches new bike Splendor iSmart at Rs 47,250.
*Mercedes slashes S Class price by Rs 21 lakh.
*Analysts see Rajan not losening rates despite better CPI data.
*Late sell-off drags Nifty below 6500; Infosys, Sun Pharma tank.
*Export benefits not completely over for India: FIEO.
*Private banks at high risk of losing customers: IBM study.